Zepbound Is Now FDA-Approved for Sleep Apnea — Here's What That Means
Tirzepatide for Sleep Apnea
For the first time in history, there is a prescription medication approved to treat obstructive sleep apnea. On December 20, 2024, the FDA approved Zepbound (tirzepatide) — the same injection used for weight loss — as the first and only medication for adults with moderate-to-severe obstructive sleep apnea and obesity.2
Here in Shreveport and across northwest Louisiana, this is significant news. Our region has some of the highest obesity rates in the country, and obesity is the leading risk factor for sleep apnea. For the millions of patients who struggle with CPAP machines — or who didn't know their sleep apnea was connected to their weight — this approval opens a new door.
What Is Obstructive Sleep Apnea?
Obstructive sleep apnea (OSA) happens when the muscles and soft tissues in the back of the throat relax and block the airway during sleep. When this happens, breathing stops — sometimes dozens or even hundreds of times a night. The brain jolts the body awake just enough to restart breathing, often without the person ever realizing it.
The most common symptoms are loud snoring, waking up tired no matter how long you sleep, morning headaches, trouble concentrating, and mood changes. Left untreated, sleep apnea raises the risk of high blood pressure, heart disease, stroke, type 2 diabetes, and depression.
About 30 million Americans have OSA — and up to 80% don't know it.2 In the South, where obesity rates are highest, those numbers are even more striking.
The Standard Treatment — and Its Limitations
For decades, the gold standard treatment for sleep apnea has been CPAP (Continuous Positive Airway Pressure) therapy — a machine that delivers a steady stream of air through a mask to keep the airway open while you sleep. CPAP is effective when used consistently, but many patients find it uncomfortable, claustrophobic, or difficult to tolerate long-term. Studies suggest that up to half of patients stop using CPAP within a year.3
Until now, patients who couldn't tolerate CPAP had limited options — positional therapy, oral appliances, or surgery. There was no medication that addressed the underlying biology of the disease.
That changed in December 2024.
The SURMOUNT-OSA Trial: What Researchers Found
The FDA approval was based on results from the SURMOUNT-OSA trial, a Phase 3, double-blind, randomized, placebo-controlled study published in the New England Journal of Medicine in June 2024 and led by Dr. Atul Malhotra of UC San Diego — one of the country's leading sleep medicine researchers.2
The trial enrolled 469 adults with moderate-to-severe OSA and obesity. Researchers ran two parallel studies: one for people who were unable or unwilling to use CPAP (Trial 1), and one for people who were already on CPAP therapy (Trial 2). Participants received either tirzepatide (10 mg or 15 mg) or placebo by injection once a week for 52 weeks.
The primary measure was the apnea-hypopnea index (AHI) — the number of times per hour breathing stops or becomes dangerously shallow during sleep. A normal AHI is under 5. Moderate sleep apnea is 15–30 events per hour; severe is above 30.
The results were striking:
| Outcome | Tirzepatide | Placebo |
|---|---|---|
| AHI reduction (Trial 1 — no CPAP) | −25.3 events/hour | −5.3 events/hour |
| AHI reduction (Trial 2 — on CPAP) | −29.3 events/hour | −5.5 events/hour |
| OSA remission or mild disease (Trial 1) | 43% | 16% |
| OSA remission or mild disease (Trial 2) | 51.5% | 14% |
| Average body weight lost | 18–20% (~45–50 lbs) | 2% (~4–6 lbs) |
"The results of the study have demonstrated the ability of tirzepatide to address both obesity and sleep apnea, offering an effective and comprehensive treatment solution," said Dr. Malhotra.2
Beyond the breathing numbers, tirzepatide also reduced inflammation (measured by hsCRP), lowered systolic blood pressure, and improved patients' own ratings of their sleep quality and daytime functioning.2
Why Does a Weight Loss Drug Help Sleep Apnea?
The link between weight and sleep apnea is direct. Excess weight — particularly fat tissue around the neck and throat — narrows the airway and makes it more likely to collapse during sleep. Losing weight reduces that pressure and often dramatically improves breathing at night.
Tirzepatide works by activating two gut hormones — GLP-1 and GIP — that reduce appetite and regulate metabolism. Because it produces significant, sustained weight loss (18–20% in SURMOUNT-OSA), it removes a core driver of airway obstruction. In roughly half of patients in the trial, that was enough to push OSA into remission or the mild category.
Who Is This Approved For?
Zepbound's FDA approval for sleep apnea is specifically for adults who have both moderate-to-severe OSA and obesity. It is not approved as a standalone replacement for CPAP in all patients — rather, it's intended to be used alongside a reduced-calorie diet and increased physical activity, and can be used whether or not the patient is currently on CPAP therapy.
This matters clinically. If you've been told you have sleep apnea but struggle with CPAP, or if you have sleep apnea alongside significant excess weight, tirzepatide may now be an option worth discussing with your doctor — not just for weight loss, but for the OSA itself. At Shreveport Direct Care, Dr. Bass reviews each patient's full medical picture before recommending any treatment. Weight management and sleep health are connected in more ways than most people realize, and addressing one often improves the other. Our physician-led membership program — starting at $109/month — includes the kind of ongoing, relationship-based care these conversations require.
What This Means for Patients in Shreveport and the Ark-La-Tex
Louisiana ranks consistently among the top states for obesity, and obesity drives sleep apnea rates that are higher than the national average in communities like ours. Many patients in this region have undiagnosed sleep apnea, or they've been diagnosed and prescribed CPAP but stopped using it.
For those patients, the availability of an FDA-approved medication that treats the root cause — excess weight — while simultaneously reducing sleep apnea severity is a genuine clinical advance. It doesn't replace CPAP for everyone, but it gives physicians and patients a meaningful new tool.
If you snore loudly, wake up exhausted, or have been told you stop breathing at night, it's worth talking to a doctor about whether you should be evaluated for sleep apnea — and whether treatments like tirzepatide might be right for you.
Ready to talk about your sleep and weight health? Schedule a free meet-and-greet with Dr. Bass at Shreveport Direct Care. We'll review your full health history, discuss your symptoms, and help you understand your options — including whether Zepbound is a candidate for you.
📞 318-588-7060 | ✉️ info@shreveportdirectcare.com
FAQs
1. What is Zepbound approved for in sleep apnea? Zepbound (tirzepatide) is FDA-approved for the treatment of moderate-to-severe obstructive sleep apnea in adults who also have obesity. It was approved December 20, 2024 — the first medication ever approved specifically for OSA.
2. Does Zepbound replace CPAP therapy? Not necessarily. Zepbound can be used whether or not a patient is on CPAP. In the SURMOUNT-OSA trial, it reduced sleep apnea severity significantly in both groups. For patients who cannot tolerate CPAP, it offers a medication-based alternative; for those who use CPAP, it may improve outcomes further.
3. How much did tirzepatide reduce sleep apnea in the trial? Tirzepatide reduced the number of breathing disruptions per hour by 25–29 events compared to 5–6 with placebo. About 43–51.5% of tirzepatide patients achieved OSA remission or mild disease, versus 14–16% with placebo.
4. How much weight did patients lose in the SURMOUNT-OSA trial? Participants on tirzepatide lost an average of 18–20% of their body weight (approximately 45–50 lbs) over 52 weeks, compared to about 2% with placebo.
5. How do I find out if I have sleep apnea in Shreveport? Talk to your primary care physician. At Shreveport Direct Care, Dr. Bass can evaluate your symptoms, order appropriate testing, and discuss whether treatment with tirzepatide or other approaches is right for you. Schedule a free meet-and-greet to get started.
References
Malhotra A, Bednarik J, Chakladar S, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. N Engl J Med. 2024;391(13):1193–1205. doi:10.1056/NEJMoa2404881
American Academy of Sleep Medicine. Obstructive sleep apnea. Sleep Education. https://sleepeducation.org/sleep-disorders/obstructive-sleep-apnea/
Weaver TE, Grunstein RR. Adherence to continuous positive airway pressure therapy: the challenge to effective treatment. Proc Am Thorac Soc. 2008;5(2):173–178. doi:10.1513/pats.200708-119MG
American Academy of Sleep Medicine. Zepbound approved by FDA as first sleep apnea medication. AASM.org. December 21, 2024. https://aasm.org/zepbound-approved-fda-first-sleep-apnea-medication/
Shreveport Direct Care is a direct primary care practice serving adults and children in Shreveport, Bossier City, and surrounding communities in Northwest Louisiana. Dr. Pat "Ricky" Bass III is board-certified in Internal Medicine and Pediatrics.